Desertomycin G, a New Antibiotic with Activity against Mycobacterium tuberculosis and Human Breast Tumor Cell Lines Produced by Streptomyces althioticus MSM3, Isolated from the Cantabrian Sea Intertidal Macroalgae Ulva sp.

• Published in: Marine Drugs
• Main Authors: Braña, Alfredo F, Sarmiento-Vizcaíno, Aida, Pérez-Victoria, Ignacio, Martín, Jesús, Otero, Luis, Palacios-Gutiérrez, Juan José, Fernández, Jonathan, Mohamedi, Yamina, Fontanil, Tania, Salmón, Marina, Cal, Santiago, Reyes, Fernando, García, Luis A, Blanco, Gloria
• Format: Article in Journal/Newspaper
• Language: English
• Published: 2019
• Subjects: Streptomyces; actinomycetes; desertomycin; intertidal seaweed; macrolide; seaweed associated actinobacteria; Antibiotics; Antineoplastic; Antitubercular Agents; Biological Products; Cell Line; Tumor; Drug Screening Assays; Antitumor; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Macrolides; Microalgae; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Northeast Atlantic
• Online Access: http://hdl.handle.net/10668/13559; https://doi.org/10.3390/md17020114; https://www.mdpi.com/1660-3397/17/2/114/pdf?version=1550234108; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409695/pdf

The isolation and structural elucidation of a structurally new desertomycin, designated as desertomycin G (1), with strong antibiotic activity against several clinically relevant antibiotic resistant pathogens are described herein. This new natural product was obtained from cultures of the marine actinomycete Streptomyces althioticus MSM3, isolated from samples of the intertidal seaweed Ulva sp. collected in the Cantabrian Sea (Northeast Atlantic Ocean). Particularly interesting is its strong antibiotic activity against Mycobacterium tuberculosis clinical isolates, resistant to antibiotics in clinical use. To the best of our knowledge, this is the first report on a member of the desertomycin family displaying such activity. Additionally, desertomycin G shows strong antibiotic activities against other relevant Gram-positive clinical pathogens such as Corynebacterium urealyticum, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecium, Enterococcus faecalis, and Clostridium perfringens. Desertomycin G also displays moderate antibiotic activity against relevant Gram-negative clinical pathogens such as Bacteroides fragilis, Haemophilus influenzae and Neisseria meningitidis. In addition, the compound affects viability of tumor cell lines, such as human breast adenocarcinoma (MCF-7) and colon carcinoma (DLD-1), but not normal mammary fibroblasts.